Phil Nadeau
Stock Analyst at TD Cowen
(2.75)
# 1,929
Out of 4,839 analysts
22
Total ratings
47.62%
Success rate
32.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Reiterates: Buy | n/a | $5.71 | - | 1 | Nov 21, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $62.17 | +4.55% | 2 | Nov 6, 2024 | |
| BIIB Biogen | Maintains: Buy | $300 → $275 | $125.51 | +119.11% | 6 | Oct 31, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $57.49 | +108.73% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $435.81 | +14.73% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $16.45 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $38.60 | - | 1 | Jul 7, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $5.90 | - | 1 | Nov 23, 2021 | |
| ANNX Annexon | Initiates: Outperform | n/a | $2.04 | - | 1 | Aug 18, 2020 | |
| KZR Kezar Life Sciences | Initiates: Outperform | n/a | $3.89 | - | 1 | Jul 16, 2018 |
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $5.71
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $62.17
Upside: +4.55%
Biogen
Oct 31, 2024
Maintains: Buy
Price Target: $300 → $275
Current: $125.51
Upside: +119.11%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $57.49
Upside: +108.73%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $435.81
Upside: +14.73%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $16.45
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $38.60
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.90
Upside: -
Annexon
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.04
Upside: -
Kezar Life Sciences
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $3.89
Upside: -